Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-08-23
2008-09-23
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S563000, C514S567000, C562S444000, C562S450000, C562S453000
Reexamination Certificate
active
07427600
ABSTRACT:
The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.
REFERENCES:
patent: 3843696 (1974-10-01), Wagner et al.
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3878187 (1975-04-01), Schneider et al.
patent: 3884898 (1975-05-01), Schneider
patent: 3975342 (1976-08-01), Gross
patent: 3998799 (1976-12-01), Bodor et al.
patent: 4025501 (1977-05-01), Leute
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4297346 (1981-10-01), Rips et al.
patent: 4346166 (1982-08-01), Montag et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4457907 (1984-07-01), Porter
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4584398 (1986-04-01), Kuroiwa et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5026827 (1991-06-01), Miyazaki et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5183883 (1993-02-01), Tanaka et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5424292 (1995-06-01), Pellicciari et al.
patent: 5501987 (1996-03-01), Ordonez et al.
patent: 5529915 (1996-06-01), Phillips et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5792786 (1998-08-01), Whittaker et al.
patent: 5811127 (1998-09-01), Milstein et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6043230 (2000-03-01), Arimilli et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6075120 (2000-06-01), Cheronis et al.
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6235718 (2001-05-01), Balasubramanium
patent: 6255285 (2001-07-01), Kotake
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6740641 (2004-05-01), Gao
patent: 6784186 (2004-08-01), Jackson
patent: 7060708 (2006-06-01), Piccariello et al.
patent: 2001/0031873 (2001-10-01), Greenwald et al.
patent: 2002/0059013 (2002-05-01), Rajala et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0151526 (2002-10-01), Gallop et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2003/0091593 (2003-05-01), Bachmann et al.
patent: 2004/0063628 (2004-04-01), Piccariello et al.
patent: 2004/0204434 (2004-10-01), Shafer
patent: 2005/0038121 (2005-02-01), Mickle et al.
patent: 2005/0054561 (2005-03-01), Mickle et al.
patent: 2005/0065086 (2005-03-01), Mickle et al.
patent: 2005/0069550 (2005-03-01), Mickle et al.
patent: 2005/0080012 (2005-04-01), Mickle et al.
patent: 2005/0176644 (2005-08-01), Mickle et al.
patent: 2005/0176645 (2005-08-01), Mickle et al.
patent: 2005/0176646 (2005-08-01), Mickle et al.
patent: 2005/0266070 (2005-12-01), Mickle et al.
patent: 2006/0014697 (2006-01-01), Mickle et al.
patent: 54168/65 (1965-01-01), None
patent: 0 187 547 (1987-07-01), None
patent: 1421130 (1965-01-01), None
patent: 1092089 (1967-11-01), None
patent: 1112347 (1968-05-01), None
patent: 94/11021 (1994-05-01), None
patent: WO 95/12605 (1995-05-01), None
patent: WO 95/14033 (1995-05-01), None
patent: 97/36616 (1997-10-01), None
patent: WO 97/36616 (1997-10-01), None
patent: WO 98/04277 (1998-02-01), None
patent: WO 99/49901 (1999-10-01), None
patent: 0037103 (2000-06-01), None
patent: 00/52078 (2000-09-01), None
patent: 00/53233 (2000-09-01), None
patent: WO 02/34237 (2002-05-01), None
patent: 03/034980 (2003-05-01), None
Jung et al. Synthesis and In Vitro/In Vivo Evaluation of 5-Aminosalicyl-Glycine . . . Journal Of Pharmaceutical Sciences. May 2000, vol. 89, No. 5, pp. 594-602.
Franssen et al. Low Molecular Weight Proteins as Carriers . . . Journal of Medicinal Chemistry. 1992, vol. 35, No. 7, pp. 1246-1259.
Kinoshita et al. Serum Leucine Aminopeptidase Assay . . . Japanese Journal of Clinical Chemistry. 1993, vol. 22, pp. 143-146.
Weber et al. Synthesis, In Vitro Skin Permeation Studies . . . Pharmaceutical Research. May 2001, vol. 18, No. 5, pp. 600-607.
Aggarwal, et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine,”J. Med. Chem., 33(5):1505-1511 (1990).
Amidon, G., et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability,”Pharmaceutical Research, vol. 12, No. 3 (1995).
Amidon, G.L., et al., “5-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT are Absorbed by the Intestinal PEPT1 Peptide Transporter,”Pharm Res. 16(2):175 (1999), Abstract.
Balimane, P., et al., “Effect of Ionization on the Variable Uptake of Valacyclovir via the Human Intestinal Peptide Transporter (hPepT1) in CHP cells,”Biopharm Drug Dispos, 21(5):165-174 (2000), Abstract.
Balimane, P.V., et al., “Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir,”Biochem Biophys Res Commun, 250(2):246-251 (1998), Abstract.
Bunevicius, R., “Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism,”The New England Journal of Medicine, vol. 340, No. 6 (1999).
Burnette, Thimysta C., et al., “Metabolic Disposition of the Acyclovir Prodrug Valaciclovir in the Rat,”Drug Metabolism and Disposition, 22(1):60-64 (1994).
Canaris, G., “The Colorado Thyroid Disease Prevalence Study,” Archives Internal Medicine Articles and Abstracts, vol. 160, No. 4 (2000).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestinal Cell Line, Caco-2,”Journal of Pharmacology and Experimental Therapeutics, 286(2):1166-1170 (1988).
Friedrichsen, G.M., et al., “Model Prodrugs Designed for the Intestinal Peptide Transporter. A Synthetic Approach for Coupling of Hydroxy-Containing Compounds to Dipeptides,”Eur J Pharm Sci, 14(1):13-19 (2001, Abstract.
Guo, A., et al., “Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Pharmacol Exp Ther, 289(1):448-454 (1999), Abstract.
Han H., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT and Absorbed by the Intestinal PEPT1 Peotide Transporter,”Pharm Res, 15(8):1154-1159 (1998), Abstract.
Han, H.K., et al., “Cellular Uptake Mechanism of Amino Acid Ester produces in Caco-2hPEPT1 Cells Overexpressing a Human Peptide Transporter,”Pharm Res, 15(9):1382-1386 (1998), Abstract.
Han, Hyo-Kyung, et al., “Targeted Prodrug Design to Optimize Drug Delivery,”AAPS PharmSci, 2(1): Article 6 (2000).
Havranova, Marie et al., “A High-Molecular Mass Derivative of Trypsin-Kallikrein Inhibitor for Potential Medical Use, II,”Hoppe-Seyler's Z. Physiol. C
Kirk Randal
Krishnan Suma
Lauderback Christopher
Mickle Travis
Moncrief James Scott
Darby & Darby P.C.
Russel Jeffrey E
Shire LLC
LandOfFree
Active agent delivery systems and methods for protecting and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Active agent delivery systems and methods for protecting and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Active agent delivery systems and methods for protecting and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3970741